Fanconi syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{Fanconi syndrome}} | {{Fanconi syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{VE}} | ||
==Overview== | ==Overview== | ||
Prevention of Fanconi syndrome mostly depends on early diagnosis, treatment and management of potential underlying diseases and/or preventing the toxicity of the exposure to exogenous precipitating factors. | |||
==Primary Prevention== | |||
Diagnosis, treatment and management of these potential underlying diseases in their early stages may prevent Fanconi syndrome's progression or even onset<ref name="pmid24076416">{{cite journal| author=Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R et al.| title=Long-term outcomes of patients with Wilson disease in a large Austrian cohort. | journal=Clin Gastroenterol Hepatol | year= 2014 | volume= 12 | issue= 4 | pages= 683-9 | pmid=24076416 | doi=10.1016/j.cgh.2013.09.025 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24076416 }}</ref><ref name="pmid25165189">{{cite journal| author=Emma F, Nesterova G, Langman C, Labbé A, Cherqui S, Goodyer P et al.| title=Nephropathic cystinosis: an international consensus document. | journal=Nephrol Dial Transplant | year= 2014 | volume= 29 Suppl 4 | issue= | pages= iv87-94 | pmid=25165189 | doi=10.1093/ndt/gfu090 | pmc=4158338 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25165189 }}</ref><ref name="pmid7927251">{{cite journal| author=van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V et al.| title=Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. | journal=Hepatology | year= 1994 | volume= 20 | issue= 5 | pages= 1187-91 | pmid=7927251 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7927251 }}</ref>: | |||
* [[Cystinosis]] medical therapy | |||
* [[Wilson's disease|Wilson disease]] medical therapy | |||
* and to a lesser extent [[Tyrosinemia]] medical therapy ( late onset Tyrosinemia lead to best results) | |||
Preventing the toxicity of the exposure to exogenous precipitating factors may prevent Fanconi syndrome's progression or even onset: | |||
* [[Galactosemia]], Galctose consumption restriction | |||
* [[Hereditary fructose intolerance]], Fructose consumption restriction | |||
* [[Tyrosinemia]], tyrosine/phenylalanine consumption restriction | |||
* Any precipitating drug or heavy metal exposure restriction or adjustment, including: ''Nucleoside Reverse Transcriptase Inhibitors, Valproic acid, Aminoglycosides, tetracyclines, cadmium and lead'' | |||
* | |||
* | |||
Latest revision as of 16:44, 21 July 2018
|
Fanconi syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fanconi syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Fanconi syndrome primary prevention |
|
Risk calculators and risk factors for Fanconi syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vahid Eidkhani, M.D.
Overview
Prevention of Fanconi syndrome mostly depends on early diagnosis, treatment and management of potential underlying diseases and/or preventing the toxicity of the exposure to exogenous precipitating factors.
Primary Prevention
Diagnosis, treatment and management of these potential underlying diseases in their early stages may prevent Fanconi syndrome's progression or even onset[1][2][3]:
- Cystinosis medical therapy
- Wilson disease medical therapy
- and to a lesser extent Tyrosinemia medical therapy ( late onset Tyrosinemia lead to best results)
Preventing the toxicity of the exposure to exogenous precipitating factors may prevent Fanconi syndrome's progression or even onset:
- Galactosemia, Galctose consumption restriction
- Hereditary fructose intolerance, Fructose consumption restriction
- Tyrosinemia, tyrosine/phenylalanine consumption restriction
- Any precipitating drug or heavy metal exposure restriction or adjustment, including: Nucleoside Reverse Transcriptase Inhibitors, Valproic acid, Aminoglycosides, tetracyclines, cadmium and lead
References
- ↑ Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R; et al. (2014). "Long-term outcomes of patients with Wilson disease in a large Austrian cohort". Clin Gastroenterol Hepatol. 12 (4): 683–9. doi:10.1016/j.cgh.2013.09.025. PMID 24076416.
- ↑ Emma F, Nesterova G, Langman C, Labbé A, Cherqui S, Goodyer P; et al. (2014). "Nephropathic cystinosis: an international consensus document". Nephrol Dial Transplant. 29 Suppl 4: iv87–94. doi:10.1093/ndt/gfu090. PMC 4158338. PMID 25165189.
- ↑ van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V; et al. (1994). "Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment". Hepatology. 20 (5): 1187–91. PMID 7927251.